Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Plinabulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 2/20 | 0.70 |
| ▸ | TUBB known ✓ | P07437 | 2/20 | 0.70 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 2/20 | 0.70 |
| ▸ | TUBA1B known ✓ | P68363 | 2/20 | 0.70 |
| ▸ | TUBA4A known ✓ | P68366 | 2/20 | 0.70 |
| ▸ | TUBB4B known ✓ | P68371 | 2/20 | 0.70 |
| ▸ | TUBB3 known ✓ | Q13509 | 2/20 | 0.70 |
| ▸ | TUBB2A known ✓ | Q13885 | 2/20 | 0.70 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 2/20 | 0.70 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 2/20 | 0.70 |
| ▸ | TUBA1A known ✓ | Q71U36 | 2/20 | 0.70 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 2/20 | 0.70 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 2/20 | 0.70 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 2/20 | 0.70 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Plinabulin SCHEMBL79095 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL29216847 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL28720406 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL21050030 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL17979608 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL31329443 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL30522117 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL31329439 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL19858952 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2C19RAF1CDK1 | |
| Plinabulin SCHEMBL31329436 | 0.94 | CYP1A2 (0.88) | CYP1A2CYP2C9CYP2C19RAF1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118304304-A | Compositions and methods for reducing neutropenia | 大连万春布林医药有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-112543636-B | Compositions and methods for treating cancers associated with EGFR mutations | 大连万春布林医药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-113613654-B | Application of plinabulin in preparation of medicine for increasing haptoglobin of non-metastatic breast cancer patient | 大连万春布林医药有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117100753-A | Use of Plinabulin in combination with immune checkpoint inhibitors | 大连万春布林医药有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-114276332-B | Polymorphic form of dehydrogenated phenyl-achyranthes and its preparing and purifying process and application | 深圳华大海洋科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-113735834-B | Plinabulin composition | 大连万春布林医药有限公司 | 2023-06-13 | — | — | CN | disclosed |